Ticker brief

IRD

last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
7
authors 14d
7
crowd 14d
+0.28

No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.

Sentiment — last 14 days
daily mean sentiment, 2026-10-05 → 2026-10-16 · now +0.35 (−1 bearish … +1 bullish)
Who spoke7
authorgradetrader scoresignalsmean sent
@QuasarMarketsC+3.671+0.00
@VistaPResearchC·1+0.35
@Brad_E_SchulzC·1+0.30
@BornInvestorC-1.001+0.55
@PrismMarketViewC·1+0.25
@OpenOutcrierC·1+0.20
@BPharmCatalystC·1+0.50
Recent signals7of 7 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-10-16@BPharmCatalyst+0.50IRD announces FDA approval of its supplemental application for phentolamine treating presbyopia.·
2026-10-16@OpenOutcrier+0.20Opus Genetics reported early trial results for gene therapies, without outcome details in the tweet.·
2026-10-08@PrismMarketView+0.25Presents five public companies as an eye-care access and treatment thematic basket.·
2026-10-08@BornInvestor+0.55A near-term biotech catalyst and 36% short float are framed as potential fuel for a large move.·
2026-10-07@Brad_E_Schulz+0.30Quantifies intraday sector breadth and performance; ticker output is capped at six movers.·
2026-10-05@VistaPResearch+0.35Frames the Nobel Prize in Medicine as illuminating a new bull market for brain-science companies.·
2026-10-05@QuasarMarkets+0.00Lists dated 2026 regulatory decisions for CAPR and IRD drug candidates.·

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.